Abstract
Background/objectives:
Studies have observed associations between the gut microbiome and obesity. O-desmethylangolensin (ODMA) and equol are gut bacterial metabolites of daidzein, a compound found in high amounts in soy foods. Approximately 80–95% and 25–60% of individuals harbor gut microbial communities capable of producing ODMA or equol, respectively. Given that other phenotypes of gut bacterial metabolism of dietary compounds have been associated with obesity, we hypothesized that daidzein-metabolizing phenotypes would be associated with obesity. The objective of this study was to compare the prevalence of ODMA-producer and equol-producer phenotypes in obese, overweight and normal-weight individuals.
Subjects/methods:
Adults aged 18–95 years (n=297) provided a first-void urine sample after a 3-day soy challenge, and urinary ODMA and equol concentrations were used to classify individuals as producers or non-producers. Body mass index was calculated from self-reported weight and height.
Results:
There were 60 ODMA non-producers and 173 equol non-producers. Obese individuals were 2.8 times more likely to be ODMA non-producers (odds ratio (OR)=2.8, 95% confidence interval (CI): 1.2, 6.2) compared with normal-weight individuals, when adjusted for age, race (white vs non-white), and gender and menopausal status (male, premenopausal female and postmenopausal female). Obesity was not associated with equol-producer phenotype (OR=1.1, 95% CI: 0.5, 2.2). Stronger associations with obesity were observed in the ODMA non-producers who were also equol producers than in the equol non-producers.
Conclusions:
Results from this analysis suggest that the ODMA-producer phenotype, but not equol-producer phenotype, is associated with obesity in adults. These results support further work to replicate these findings and evaluate the mechanisms of the observed associations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Berg RD . The indigenous gastrointestinal microflora. Trends Microbiol 1996; 4: 430–435.
Hullar MA, Lampe JW . The gut microbiome and obesity. Nestle Nutr Workshop Ser 2012; 73: 67–79.
Nakamura Y, Tsuji S, Tonogai Y . Determination of the levels of isoflavonoids in soybeans and soy-derived foods and estimation of isoflavonoids in the Japanese daily intake. J AOAC Int 2000; 83: 635–650.
Setchell KD, Clerici C . Equol: pharmacokinetics and biological actions. J Nutr 2010; 140: 1363S–1368S.
Frankenfeld CL . O-desmethylangolensin: the importance of equol's lesser known cousin to human health. Adv Nutr 2011; 2: 317–324.
Heinonen S, Wähälä K, Adlercreutz H . Identification of isoflavone metabolites dihydrodaidzein, dihydrogenistein, 6'-OH-O-dma, and cis-4-OH-equol in human urine by gas chromatography-mass spectroscopy using authentic reference compounds. Anal Biochem 1999; 274: 211–219.
Atkinson C, Frankenfeld CL, Lampe JW . Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 2005; 230: 155–170.
Setchell KD, Clerici C . Equol: history, chemistry, and formation. J Nutr 2010; 140: 1355S–1362S.
Frankenfeld CL, Atkinson C, Thomas WK, Gonzalez A, Jokela T, Wähälä K et al. High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. Br J Nutr 2005; 94: 873–876.
Song KB, Atkinson C, Frankenfeld CL, Jokela T, Wähälä K, Thomas WK et al. Prevalence of daidzein-metabolizing phenotypes differs between Caucasian and Korean American women and girls. J Nutr 2006; 136: 1347–1351.
Lampe JW . Is equol the key to the efficacy of soy foods? Am J Clin Nutr 2009; 89: 1664S–1667S.
Shor D, Sathyapalan T, Atkin S, Thatcher N . Does equol production determine soy endocrine effects? Eur J Nutr 2012; 51: 389–398.
Frankenfeld CL . Relationship of obesity and high urinary enterolignan concentrations in 6806 children and adults: analysis of National Health and Nutrition Examination Survey data. Eur J Clin Nutr 2013; 67: 887–889.
Frankenfeld CL, Atkinson C, Thomas WK, Goode EL, Gonzalez A, Jokela T et al. Familial correlations, segregation analysis, and nongenetic correlates of soy isoflavone-metabolizing phenotypes. Exp Biol Med (Maywood) 2004; 229: 902–913.
Frankenfeld CL, McTiernan A, Tworoger SS, Atkinson C, Thomas WK, Stanczyk FZ et al. Serum steroid hormones, sex hormone-binding globulin concentrations, and urinary hydroxylated estrogen metabolites in post-menopausal women in relation to daidzein-metabolizing phenotypes. J Steroid Biochem Mol Biol 2004; 88: 399–408.
World Health Organization (WHO) World Health Organization (WHO) Obesity and overweight. Fact Sheet No. 311. 2012.
Ley RE . Obesity and the human microbiome. Curr Opin Gastroenterol 2010; 26: 5–11.
Finegold SM, Attebery HR, Sutter VL . Effect of diet on human fecal flora: comparison of Japanese and American diets. Am J Clin Nutr 1974; 27: 1456–1469.
Benno Y, Endo K, Mizutani T, Namba Y, Komori T, Mitsuoka T . Comparison of fecal microflora of elderly persons in rural and urban areas of Japan. Appl Environ Microbiol 1989; 55: 1100–1105.
Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 2006; 72: 1027–1033.
Zhao L, Xu W, Ibrahim SA, Jin J, Feng J, Jiang J et al. Effects of age and region on fecal microflora in elderly subjects living in Bama, Guangxi, China. Curr Microbiol 2011; 62: 64–70.
Frankenfeld CL, McTiernan A, Aiello EJ, Thomas WK, LaCroix K, Schramm J et al. Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004; 13: 1156–1162.
Frankenfeld CL, McTiernan A, Thomas WK, LaCroix K, McVarish L, Holt VL et al. Postmenopausal bone mineral densityin relation to soy isoflavone-metabolizing phenotypes. Maturitas 2006; 53: 315–324.
Atkinson C, Newton KM, Aiello Bowles EJ, Lehman CD, Stanczyk FZ, Westerlind KC et al. Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States. Breast Cancer Res Treat 2009; 116: 587–594.
Atkinson C, Newton KM, Stanczyk FZ, Westerlind KC, Li L, Lampe JW . Daidzein-metabolizing phenotypes in relation to serum hormones and sex hormone binding globulin, and urinary estrogen metabolites in premenopausal women in the United States. Cancer Causes Control 2008; 19: 1085–1093.
Atkinson C, Newton KM, Yong M, Stanczyk FZ, Westerlind KC, Li L et al. Daidzein-metabolizing phenotypes in relation to bone density and body composition among premenopausal women in the United States. Metabolism 2012; 61: 1678–1682.
Bolca S, Van de Wiele T, Possemiers S . Gut metabotypes govern health effects of dietary polyphenols. Curr Opin Biotechnol 2012; 24: 220–225.
Schoefer L, Mohan R, Braune A, Birringer M, Blaut M . Anaerobic C-ring cleavage of genistein and daidzein by Eubacterium ramulus. FEMS Microbiol Lett 2002; 208: 197–202.
Hur HG, Beger RD, Heinze TM, Lay Jr JO, Freeman JP, Dore J et al. Isolation of an anaerobic intestinal bacterium capable of cleaving the C-ring of the isoflavonoid daidzein. Arch Microbiol 2002; 178: 8–12.
Schneider H, Blaut M . Anaerobic degradation of flavonoids by Eubacterium ramulus. Arch Microbiol 2000; 173: 71–75.
Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480–484.
Gil-Izquierdo A, Penalvo JL, Gil JI, Medina S, Horcajada MN, Lafay S et al. Soy isoflavones and cardiovascular disease epidemiological, clinical and -omics perspectives. Curr Pharm Biotechnol 2012; 13: 624–631.
Ishimi Y . Soybean isoflavones in bone health. Forum Nutr 2009; 61: 104–116.
Jackman KA, Woodman OL, Sobey CG . Isoflavones equol and cardiovascular disease: pharmacological and therapeutic insights. Curr Med Chem 2007; 14: 2824–2830.
Jackson RL, Greiwe JS, Schwen RJ . Emerging evidence of the health benefits of S-equol, an estrogen receptor beta agonist. Nutr Rev 2011; 69: 432–448.
Martin D, Song J, Mark C, Eyster K . Understanding the cardiovascular actions of soy isoflavones: potential novel targets for antihypertensive drug development. Cardiovasc Hematol Disorders Drug Targets 2008; 8: 297–312.
Wiseman H . The therapeutic potential of phytoestrogens. Exp Opin Invest Drugs 2000; 9: 1829–1840.
Yuan JP, Wang JH, Liu X . Metabolism of dietary soy isoflavones to equol by human intestinal microflora—implications for health. Mol Nutr Food Res 2007; 51: 765–781.
Setchell KD, Brown NM, Lydeking-Olsen E . The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 2002; 132: 3577–3584.
Lampe JW . Emerging research on equol and cancer. J Nutr 2010; 140: 1369S–1372S.
Takeuchi S, Takahashi T, Sawada Y, Iida M, Matsuda T, Kojima H . Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using Chinese hamster ovary cells. Biol Pharm Bull 2009; 32: 195–202.
Pfitscher A, Reiter E, Jungbauer A . Receptor binding and transactivation activities of red clover isoflavones and their metabolites. J Steroid Biochem Mol Biol 2008; 112: 87–94.
Lourdes M, Cruz A, Wong WW, Mimouni F, Hachey DL, Setchell KDR et al. Effects of infant nutrition on cholesterol synthesis rates. Pediatr Res 1994; 35: 135–140.
Acknowledgements
This work was supported by the National Institutes of Health Grants R03CA089785 and T32CA009168 (CLF). The work was carried out partially within the EU project PHYTOHEALTH QLRT-2001-02453.
DISCLAIMER
This study does not necessarily reflect the views of the commission and in no way anticipates the commission's future policy in this area.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Contributors: CLF, CA, KW and JWL contributed to the data acquisition. CLF drafted the article. All authors contributed to the concept and design, interpretation of data and revision of the article for important intellectual content, and approved the final version to be published.
Rights and permissions
About this article
Cite this article
Frankenfeld, C., Atkinson, C., Wähälä, K. et al. Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein. Eur J Clin Nutr 68, 526–530 (2014). https://doi.org/10.1038/ejcn.2014.23
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejcn.2014.23
This article is cited by
-
Interaction between gut microbiota and sex hormones and their relation to sexual dimorphism in metabolic diseases
Biology of Sex Differences (2023)
-
Production of indole and hydrogen sulfide by the oxygen-tolerant mutant strain Clostridium sp. Aeroto-AUH-JLC108 contributes to form a hypoxic microenvironment
Archives of Microbiology (2022)
-
Genetic Polymorphisms, Mediterranean Diet and Microbiota-Associated Urolithin Metabotypes can Predict Obesity in Childhood-Adolescence
Scientific Reports (2020)
-
Contribution of plant food bioactives in promoting health effects of plant foods: why look at interindividual variability?
European Journal of Nutrition (2019)
-
Soy-Induced Fecal Metabolome Changes in Ovariectomized and Intact Female Rats: Relationship with Cardiometabolic Health
Scientific Reports (2018)